Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
POPLIN: Prophylactic Tocilizumab with Linvoseltamab in Relapsed/Refractory Multiple Myeloma
NCT07609940Phase 4Recruiting
- Sponsor
- Regeneron Pharmaceuticals
- Start
- Jul 2026
- Primary completion
- Oct 2027
- Countries
- 1
01
Overview
A Phase 4 trial of tocilizumab, linvoseltamab in multiple myeloma (MM), sponsored by Regeneron Pharmaceuticals. Started Jul 2026; status: recruiting.
02
Drugs
tocilizumablinvoseltamab
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT07609940.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07609940.